How effective is Olaparib?

Olaparib has different efficacy in the treatment of different cancers. Its indications include ovarian cancer, breast cancer, pancreatic cancer, prostate cancer, etc.

1. In advanced ovarian cancer, Lynparza may help prevent ovarian cancer from growing or coming back after a response to prior platinum-based chemotherapy. Among women with BRCA mutations who responded to first-line platinum-based chemotherapy, olaparib reduced the risk of disease progression or death by 70% compared with placebo. Most women did not see their cancer grow or come back for a median of 3.4 years. Among women with and without BRCA mutations who responded to second-line chemotherapy, olaparib reduced the risk of disease progression or death by 65% u200bu200bcompared with placebo. The median time to cancer progression was 8.4 months for most women, compared with 4.8 months for women in the placebo group. Olaparibhas also shown positive results in other studies of women with advanced ovarian cancer when combined with bevacizumab (Avastin).

2. (1) In BRCA-mutated HER2-negative metastatic breast cancer, Lynparza is used to help shrink or slow the genetic growth of BRCA-mutated human epidermal growth factor receptor 2 (HER2)-negative breast cancer that has spread to other parts of the body (metastatic). The patientshould have received chemotherapy drugs, either before or after the cancer spread. If you have hormone receptor (HR)-positive breast cancer, you should receive hormone therapy. In metastatic breast cancer, olaparib delayed disease progression by 7 months compared with 4.2 months in patients treated with chemotherapy. People who received olaparib were 42% less likely to have their cancer grow or spread than those who received chemotherapy. Additionally, 52% of people saw their tumors shrink, compared with 23% of people who received certain chemotherapy treatments.

(2) In HER2-negative high-risk early-stage breast cancer with BRCA mutations, in a phase 3 study, women and men who had undergone surgery received chemotherapy before and after surgery. Some women with hormone receptor-positive breast cancer may also receive hormone therapy. In the study, 921 adults received olaparib and 915 received placebo. The study results showed that compared with placebo, olaparib reduced the risk of breast cancer recurrence by 42% (815 of 921 patients treated with olaparib did not have breast cancer recurrence, compared with 737 of 915 patients treated with placebo). Lynparza also reduced the risk of death by 32% compared with placebo (a secondary endpoint).

3. In pancreatic cancer, olaparib can be used as maintenance treatment in patients with a type of pancreatic cancer that has an abnormal gene (gBRCA mutation). It can be used when the cancer has not progressed after at least 16 weeks of first-line platinum-based chemotherapy. In one study, 92 patients received olaparib and 62 received an inactive placebo. In patients who received olaparib, the cancer did not grow or return for 7.4 months, compared with 3.8 months for those who received placebo. Compared with placebo, olaparib reduced the risk of cancer growing or coming back by 47%.

4. Olaparib is also used to treat metastatic prostate cancer that no longer responds to previous treatments or surgeries due to certain inherited or acquired abnormal genes (HRR gene mutations). In a study of men with BRCA1, BRCA2 or ATM gene mutations, olaparib doubled the median time without cancer progression or death to 7.4 months, compared with 3.6 months with the hormone treatments enzalutamide (Xtandi) or abiraterone (Yonsa, Zytiga). Overall, 35%of patients taking olaparib did not experience disease progression or death, compared with 18%of patients taking enzalutamide or abiraterone. 33%服用奥拉帕利的男性肿瘤缩小，相比之下，服用恩扎卢他胺或阿比特龙的男性肿瘤缩小率为2%。 Compared with enzalutamide or abiraterone, olaparib had a 31% lower risk of death. After starting olaparib, patients' median survival was 19.1 months, compared with 14.7 months for patients taking enzalutamide or abiraterone.

Lynparza The original drug has been launched in China and has entered the scope of Class B medical insurance, but it is only available to patients who meet the indications. The price of each box of 150mg*56 tablets may be around RMB 6,000. There are price differences for drugs of different specifications. There are also Olaparibgeneric drugs produced overseas. The specifications produced by Bangladesh pharmaceutical factories150mg*120 tablets per box may cost around RMB 4,000 (the price may fluctuate due to the exchange rate). Its drug ingredients are basically the same as those of the Olaparib original drug. For more drug information and specific prices, please consult Yaode Medical Consultant.